Journal of Psychopharmacology
February 25, 2022
Francis M. Dijkstra, Aurora JAE van de Loo, Smedra Abdulahad et al.
16 citations
Background: Intranasal esketamine demonstrates rapid improvement of depressive symptoms. However, transient adverse effects (dissociation, sedation and dizziness) may occur, which could impact driving performance. Aims: To evaluate the effects of 84 mg intranasal esketamine on driving performance in unipolar major depressive disorder (MDD) or persistent depressive disorder (PDD) patients....
Human Psychopharmacology: Clinical and Experimental
February 18, 2022
A. P. Jesus-Nunes, Gustavo C. Leal, Fernanda S. Correia-Melo et al.
39 citations
Major depressive disorder (MDD) is a leading cause of disability worldwide and most people do not achieve symptom remission. Treatment‐resistant depression (TRD) is characterized by the failure of at least one adequate trial of a major class of antidepressant, with adequate time and dosage. We aimed to identify clinical predictors of depressive symptom remission and response 24 h and 7 days...
International Journal of Drug Policy
February 9, 2022
Meryem Grabski, Jon Waldron, Tom P. Freeman et al.
BACKGROUND Esketamine was licensed for use in treatment resistant depression by the European Medicines Agency in December 2019. It is unclear whether this new approval has lowered the risk perception of recreational ketamine use. This is important given a recent increase in recreational ketamine use. METHODS This study expanded on an existing longitudinal online study of the nightlife scene, by...
The International Journal of Neuropsychopharmacology
January 12, 2022
Guang Chen, Li Chen, Yun Zhang et al.
Abstract Background In this post-hoc analysis, data from 2 positive, pivotal, phase 3 trials of esketamine nasal spray (ESK) in treatment-resistant depression (TRD)—short-term study (TRANSFORM-2) and maintenance study (SUSTAIN-1)—were analyzed to evaluate the relationship between dissociation and antidepressant effects of ESK. Methods Analysis by responder status, correlation analysis, and...
EXCLI journal
2022
Miriam Olivola, Vincenzo Arienti, Nicola Bassetti et al.
Major depression is a common comorbidity in autism spectrum disorder (ASD), often difficult to identify and to treat. Autistic subjects are more at risk for suicidal thoughts and behaviors compared to typically developing peers. Unfortunately, ASD individuals are more frequently treatment-resistant and often show side-effects which reduce efficacy. Intranasal esketamine has been recently...
Neurobiology of Stress
2022
Zhuoyu Ren, Mingling Wang, Mokhtar Aldhabi et al.
28 citations
Rapid antidepressant effects of S-ketamine have repeatedly been confirmed in patients with depression, as well as in chronic unpredictable mild stress (CUMS) animal models. However, the pharmacological study of S-ketamine for anti-postpartum depression has not been considered. In this study, the classical method of reproductive hormone withdrawal was used to construct a rat model of postpartum...
Frontiers in Psychiatry
2022
Joost J. Breeksema, Alistair Niemeijer, Bouwe Kuin et al.
41 citations
Ketamine and its enantiomer esketamine represent promising new treatments for treatment-resistant depression (TRD). Esketamine induces acute, transient psychoactive effects. How patients perceive esketamine treatment, and which conditions facilitate optimal outcomes, remains poorly understood. Understanding patient perspectives on these phenomena is important to identify unmet needs, which can...
BMC Anesthesiology
December 16, 2021
Yaqian Han, Pule Li, Mengrong Miao et al.
Background Postpartum depression (PPD) is a common complication of cesarean section. S-ketamine given intravenously during surgery can help prevent PPD. However, whether S-ketamine in patient-controlled intravenous analgesia (PCIA) can reduce the incidence of PPD is unknown. This study assessed the effect of S-ketamine as an adjuvant in PCIA for preventing PPD in women undergoing cesarean...
The Brown University Psychopharmacology Update
November 1, 2021
Extending adjunctive treatment with esketamine nasal spray over 4 weeks showed benefit in a group of patients with treatment‐resistant depression who did not respond within the first week of treatment, a post hoc analysis of two Phase 3 studies has found. The results suggest that a full 4‐week induction of esketamine with an oral antidepressant may optimize treatment outcomes, the researchers...
BMC Psychiatry
October 31, 2021
Nagahide Takahashi, Aya Yamada, Ayako Shiraishi et al.
56 citations
Abstract Background Esketamine nasal spray (Spravato) in conjunction with oral antidepressants (ADs) is approved in the European Union, United States, and other markets for treatment-resistant depression (TRD). Efficacy, safety, and tolerability of esketamine nasal spray in Japanese patients with TRD needs to be assessed. Methods This Phase 2b, randomized, double-blind (DB), placebo-controlled...